The present disclosure relates to a compound represented by Chemical Formula 1 and an antibacterial pharmaceutical composition, an antibacterial food composition, an antibacterial cosmetic composition or an antibacterial feed composition comprising the compound as an active ingredient, and has excellent inhibitory activity against Mycoplasma, and thus may be usefully used to prevent or treat infectious diseases caused by Mycoplasma.

The present technology provides disulfide-containing lipopeptides of Formula I. Such lipids may be incorporated into lipid nanoparticles for delivery of nucleic acids, nucleotides (e.g., NAD.sup.+ or NADH), polypeptides (including proteins), and complexes of proteins and nucleic acids, e.g., Cas9 RNP. The present technology also provides methods for delivering the nanoparticles to a cell and methods of treating a condition or disorder using the lipid nanoparticles.

Prodrugs (I) and (Ia) of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases. ##STR00001##

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

The present invention relates to the field of molecular biochemistry and medicine, and in particular to ligands comprising modified amino acid residues, targeting the amyloid- peptide associated with Alzheimer's disease for prevention of aggregation, neurotoxicity and use thereof as drugs for treatment of Alzheimer's disease.

Compounds for targeting and agents for imaging, Prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

The present invention provides a nano particle comprising: a core comprising metal atoms; a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprises: at least one carbohydrate ligand; at least one glutathione ligand; and at least one autoantigen peptide ligand. Also provided are compositions and vaccines comprising the nanoparticles, methods for producing the nanoparticles and medical uses of the nanoparticles, including for antigen specific imunotherapy of an autoimmune disease, such as diabetes mellitus type 1, in a mammalian subject.